NCT06527222View on ClinicalTrials.gov

A Study of Ranolazine in ALS

PHASE2RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

April 29, 2025

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Ranolazine

500mg twice daily

DRUG

Ranolazine

1000 mg twice daily

DRUG

Placebo

Ranolazine placebo twice daily

Trial Locations (7)

32224

RECRUITING

Mayo Clinic Florida, Jacksonville

43210

RECRUITING

The Ohio State University, Columbus

53226

NOT_YET_RECRUITING

The Medical College of Wisconsin, Milwaukee

65212

RECRUITING

University of Missouri Health Care, Columbia

66205

RECRUITING

University of Kansas Medical Center, Fairway

67214

RECRUITING

University of Kansas Medical Center: Wichita, Wichita

94143

RECRUITING

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

ALS Association

OTHER

lead

Swathy Chandrashekhar, MBBS

OTHER